Ophthalmic device for drug delivery

US11298262B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11298262-B2
Application numberUS-201916516356-A
CountryUS
Kind codeB2
Filing dateJul 19, 2019
Priority dateJul 23, 2018
Publication dateApr 12, 2022
Grant dateApr 12, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An ophthalmic implant for drug delivery. The implant includes a primary intracapsular device coupled to a secondary device, wherein, when implanted in a patient's eye, the primary intracapsular device is held in place by the patient's capsular bag and the secondary device is held in place by the primary intracapsular device. The implant may be inserted in the eye by injecting the primary intracapsular device into the eye either before or after attaching the secondary device to the primary intracapsular device, and subsequently positioning the joined secondary device and primary intracapsular device with the primary intracapsular device held in place by the patient's capsular bag and the secondary device held in place by the primary intracapsular device. The secondary device may be designed to hold a tertiary device that can be implanted and attached at the time of surgery or anytime postoperatively.

First claim

Opening claim text (preview).

What is claimed is: 1. An ophthalmic implant comprising: a multi-part IOL assembly comprising a primary device ( 23 ) comprising an IOL ( 22 ) and a secondary device comprising a first drug delivery device ( 30 ); wherein: said IOL ( 22 ) comprising a lens ( 24 ), a tab ( 26 ), and a haptic ( 28 ); said tab ( 26 ) extending from the IOL ( 22 ), and said tab ( 26 ) configured to engage the first drug delivery device ( 30 ); said haptic ( 28 ) extending radially outwardly from the lens ( 24 ), such that said haptic ( 28 ) is configured to hold the IOL ( 22 ) in place within a capsular bag of a patient's eye; said first drug delivery device ( 30 ) comprises a ring configured for a mechanical fit on the tab ( 26 ); and in an assembled configuration, the first drug delivery device ( 30 ) is engaged in said mechanical fit with the tab ( 26 ) to secure the first drug delivery device ( 30 ) to the IOL ( 22 ) such that the tab ( 26 ) extends from the IOL ( 22 ) through a hole in the first drug delivery device ( 30 ) to establish said mechanical fit on the tab ( 26 ). 2. The ophthalmic implant of claim 1 , wherein: the first drug delivery device ( 30 ) comprises a drug pad integrated into the first drug delivery device ( 30 ). 3. The ophthalmic implant of claim 1 , wherein: the first drug delivery device ( 30 ) is further configured to comprise a drug pad. 4. The ophthalmic implant of claim 1 , wherein: the first drug delivery device ( 30 ) further comprises a refillable reservoir. 5. The ophthalmic implant of claim 1 , further comprising: a second drug delivery device ( 39 ) configured for attachment to the first drug delivery device ( 30 ). 6. The ophthalmic implant of claim 1 , wherein: the haptic ( 28 ) extending radially outwardly from the lens ( 24 ) extends outwardly in a plane of the lens. 7. The ophthalmic implant of claim 1 , wherein: the IOL ( 22 ) has an anterior side ( 24 ) and is configured for placement into the eye of a patient with said anterior side ( 24 ) disposed anteriorly in the eye of the patient; and the tab ( 26 ) extends from the anterior side ( 24 ) of the IOL ( 22 ).

Assignees

Inventors

Classifications

  • A61F2/1613Primary

    having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus · CPC title

  • Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements · CPC title

  • having filiform haptics · CPC title

  • Intraocular lenses · CPC title

  • Implant having one or more holes, e.g. for nutrient transport, for facilitating handling · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11298262B2 cover?
An ophthalmic implant for drug delivery. The implant includes a primary intracapsular device coupled to a secondary device, wherein, when implanted in a patient's eye, the primary intracapsular device is held in place by the patient's capsular bag and the secondary device is held in place by the primary intracapsular device. The implant may be inserted in the eye by injecting the primary intrac…
Who is the assignee on this patent?
Univ Colorado Regents, Spyglass Pharma Inc
What technology area does this patent fall under?
Primary CPC classification A61F2/1613. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).